Cellebrite DI (CLBT) to Release Earnings on Wednesday

Cellebrite DI (NASDAQ:CLBT) is projected to release its Q3 2025 results after the market closes on Wednesday, November 12th. Analysts expect Cellebrite DI to post earnings of $0.13 per share and revenue of $122.9750 million for the quarter. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 5:00 PM ET.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings data on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.01. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The company had revenue of $113.28 million for the quarter, compared to analyst estimates of $112.33 million. During the same period in the previous year, the company posted $0.10 EPS. The firm’s revenue for the quarter was up 18.4% compared to the same quarter last year. On average, analysts expect Cellebrite DI to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cellebrite DI Trading Down 4.3%

Shares of Cellebrite DI stock opened at $15.90 on Wednesday. Cellebrite DI has a 12-month low of $13.10 and a 12-month high of $26.30. The company has a market cap of $3.81 billion, a price-to-earnings ratio of -20.92, a PEG ratio of 3.16 and a beta of 1.29. The company’s 50-day moving average price is $17.82 and its 200-day moving average price is $16.82.

Institutional Investors Weigh In On Cellebrite DI

A number of institutional investors and hedge funds have recently bought and sold shares of CLBT. SkyView Investment Advisors LLC raised its stake in shares of Cellebrite DI by 2.6% during the second quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock worth $597,000 after acquiring an additional 970 shares in the last quarter. Tidal Investments LLC raised its stake in shares of Cellebrite DI by 60.9% during the second quarter. Tidal Investments LLC now owns 96,157 shares of the company’s stock worth $1,539,000 after acquiring an additional 36,402 shares in the last quarter. Select Equity Group L.P. purchased a new position in shares of Cellebrite DI during the second quarter worth approximately $5,558,000. Man Group plc increased its stake in shares of Cellebrite DI by 44.1% in the second quarter. Man Group plc now owns 731,589 shares of the company’s stock worth $11,705,000 after buying an additional 223,941 shares during the period. Finally, HRT Financial LP increased its stake in shares of Cellebrite DI by 89.3% in the second quarter. HRT Financial LP now owns 217,360 shares of the company’s stock worth $3,477,000 after buying an additional 102,520 shares during the period. 45.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CLBT. JPMorgan Chase & Co. increased their price target on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock an “overweight” rating in a report on Wednesday, September 24th. Weiss Ratings reissued a “sell (d+)” rating on shares of Cellebrite DI in a report on Wednesday, October 8th. Lake Street Capital lowered their price target on shares of Cellebrite DI from $24.00 to $22.00 and set a “buy” rating on the stock in a report on Friday, August 15th. Needham & Company LLC lowered their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, August 14th. Finally, Wall Street Zen raised shares of Cellebrite DI from a “hold” rating to a “buy” rating in a report on Friday, September 26th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $21.75.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.